Liver Transplant Rejection - Pipeline Review, H2 2016; New Report Launched

Market Research Reports, Inc. has announced the addition of “Liver Transplant Rejection - Pipeline Review, H2 2016” research report to their website www.MarketResearchReports.com

Logo

Lewes, DE -- (SBWire) -- 11/02/2016 --Liver Transplant Rejection – Pipeline Review, H2 2016; Liver Transplant Rejection pipeline therapeutics constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore Liver Transplant Rejection Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it.

Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The report 'Liver Transplant Rejection – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

For more information Visit at: http://www.marketresearchreports.com/global-markets-direct/liver-transplant-rejection-pipeline-review-h2-2016

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions

Media Relations Contact

Sudeep Chakravarty
Director - Operations
Market Research Reports, Inc.
302-703-7787
http://www.marketresearchreports.com/global-markets-direct/liver-transplant-rejection-pipeline-review-h2-2016

View this press release online at: http://rwire.com/738092